MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer
Public ClinicalTrials.gov record NCT00003736. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study: High Risk Breast Cancer Screening Pilot Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for breast cancer. Diagnostic procedures such as MRI may improve the ability to detect breast cancer. PURPOSE: Screening and diagnostic trial to study the effectiveness of MRI scans in women who are at high risk for developing breast cancer.
Study identification
- NCT ID
- NCT00003736
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Interventions
- motexafin gadolinium Drug
- biopsy Procedure
- breast imaging study Procedure
- comparison of screening methods Procedure
- magnetic resonance imaging Procedure
- study of high risk factors Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 25 Years to 120 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 1999
- Primary completion
- May 31, 2002
- Completion
- May 31, 2002
- Last update posted
- Sep 23, 2019
1999 – 2002
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Cancer Center and Cancer Research Institute | San Francisco | California | 94143-0128 | — |
| University of Colorado Cancer Center | Denver | Colorado | 80010 | — |
| Porter Adventist Hospital | Denver | Colorado | 80210 | — |
| Hartford Hospital | Hartford | Connecticut | 06102-5037 | — |
| Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| Lineberger Comprehensive Cancer Center, UNC | Chapel Hill | North Carolina | 27599-7295 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104-4283 | — |
| Simmons Cancer Center - Dallas | Dallas | Texas | 75235-9154 | — |
| Cancer Center at the University of Virginia | Charlottesville | Virginia | 22908 | — |
| University of Washington Medical Center | Seattle | Washington | 98195-6043 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003736, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2019 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003736 live on ClinicalTrials.gov.